Zevra Therapeutics (NASDAQ:ZVRA) Sets New 52-Week High - Still a Buy?

Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Get Free Report) reached a new 52-week high during mid-day trading on Thursday . The stock traded as high as $11.84 and last traded at $11.56, with a volume of 1000847 shares changing hands. The stock had previously closed at $11.55.

Wall Street Analysts Forecast Growth

ZVRA has been the subject of a number of research reports. Wall Street Zen upgraded shares of Zevra Therapeutics from a "hold" rating to a "buy" rating in a research note on Thursday, May 22nd. Canaccord Genuity Group increased their target price on shares of Zevra Therapeutics from $23.00 to $25.00 and gave the company a "buy" rating in a research note on Thursday, March 13th. Cantor Fitzgerald raised their price target on shares of Zevra Therapeutics from $25.00 to $29.00 and gave the stock an "overweight" rating in a research note on Thursday. HC Wainwright started coverage on shares of Zevra Therapeutics in a research note on Wednesday, July 2nd. They issued a "buy" rating and a $26.00 price target on the stock. Finally, Guggenheim raised their price target on shares of Zevra Therapeutics from $20.00 to $22.00 and gave the company a "buy" rating in a report on Thursday, March 13th. Nine investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Buy" and a consensus price target of $23.71.

Zevra Therapeutics Price Performance

The company has a market capitalization of $670.65 million, a PE ratio of -6.46 and a beta of 1.97. The company has a debt-to-equity ratio of 1.46, a current ratio of 3.02 and a quick ratio of 2.93. The company's 50 day simple moving average is $8.97 and its 200 day simple moving average is $8.18.

Zevra Therapeutics (NASDAQ:ZVRA - Get Free Report) last released its earnings results on Tuesday, May 13th. The company reported ($0.06) EPS for the quarter, beating analysts' consensus estimates of ($0.21) by $0.15. Zevra Therapeutics had a negative return on equity of 201.05% and a negative net margin of 226.78%. The company had revenue of $20.40 million during the quarter, compared to the consensus estimate of $16.96 million. During the same quarter last year, the company earned ($0.40) earnings per share. As a group, sell-side analysts predict that Zevra Therapeutics, Inc. will post -1.95 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. BNP Paribas Financial Markets purchased a new position in shares of Zevra Therapeutics during the 4th quarter valued at approximately $53,000. GAMMA Investing LLC grew its holdings in Zevra Therapeutics by 20,564.1% during the first quarter. GAMMA Investing LLC now owns 8,059 shares of the company's stock worth $60,000 after acquiring an additional 8,020 shares during the period. Squarepoint Ops LLC increased its stake in Zevra Therapeutics by 36.1% in the 4th quarter. Squarepoint Ops LLC now owns 16,534 shares of the company's stock worth $138,000 after purchasing an additional 4,384 shares in the last quarter. Strs Ohio acquired a new stake in Zevra Therapeutics during the 1st quarter worth about $125,000. Finally, ProShare Advisors LLC acquired a new stake in Zevra Therapeutics during the 4th quarter worth about $145,000. Institutional investors and hedge funds own 35.03% of the company's stock.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.